Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here’s Why Qiagen Skyrocketed Over 43% in November

By Brian Orelli, PhD - Dec 4, 2019 at 1:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Buyout speculation buoys the test maker.

What happened

Shares of Qiagen ( QGEN -0.66% ) jumped 43.6% in November, according to data provided by S&P Global Market Intelligence, after the maker of scientific and diagnostic tests said that it was considering a potential sale of the company.

So what

Bloomberg initially reported that Thermo Fisher Scientific ( TMO 1.36% ) was looking to acquire Qiagen, although it cited unnamed sources, and the companies weren't willing to confirm that they were in talks.

And then a few days later, Qiagen acknowledged that it had received several "indications of interest" to be acquired and was exploring strategic alternatives.

After a rocky third quarter, a transition in the CEO position, and a pivot in next-generation sequencing sent Qiagen down 20% in October, it's not surprising that Thermo Fisher or some other big science and diagnostic outfit might want to swoop in and buy the company's assets on the cheap.

There's certainly been plenty of consolidation in the industry with companies looking to save money on redundancies like sales forces. Thermo Fisher is, of course, the result of the merger of Thermo Electron and Fisher Scientific.

Scientist working in a laboratory.

Image Source: Qiagen.

Now what

While an acquisition of Qiagen makes sense, there's no guarantee that management can find a buyer willing to pay what Qiagen's board believes it's worth, especially with uncertainties around how the new next-generation sequencing partnership with Illumina ( ILMN -2.85% ) will work out. Arguably, that partnership could throw a wrench into acquisition plans, considering that Thermo Fisher has its own next-generation sequencing platform called Ion Torrent.

If a deal does end up getting done, investors shouldn't expect much of a premium from here given that shares have already largely priced in a potential sale. Qiagen was a great -- albeit risky -- buy after the October drop, but at this point, investors looking for new investments should probably look at other healthcare companies.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

QIAGEN N.V. Stock Quote
QIAGEN N.V.
QGEN
$54.20 (-0.66%) $0.36
Illumina, Inc. Stock Quote
Illumina, Inc.
ILMN
$347.28 (-2.85%) $-10.20
Thermo Fisher Scientific Inc. Stock Quote
Thermo Fisher Scientific Inc.
TMO
$636.11 (1.36%) $8.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.